Doctors warn pandemic has pushed lung cancer services back 20 yearsGovernments must act to restore the damage done to lung cancer services during the pandemic in order to Share XDoctors warn pandemic has pushed lung cancer services back 20 yearshttps://pharmaphorum.com/news/pandemic-pushed-lung-cancer-services-back-20-years-leading-doctors-say/
Careology joins forces with remote care support firm RedArcDigital cancer care platform Careology has joined forces with RedArc, which provides long-term support for people with serious Share XCareology joins forces with remote care support firm RedArchttps://pharmaphorum.com/news/careology-joins-forces-with-care-support-firm-redarc/
AZ/Daiichi Sankyo’s Enhertu gets second US cancer indicationAstraZeneca and Daiichi Sankyo’s Enhertu cancer drug has picked up a second indication, in patients who have stomach Share XAZ/Daiichi Sankyo’s Enhertu gets second US cancer indicationhttps://pharmaphorum.com/news/az-daiichi-sankyos-enhertu-gets-second-us-cancer-indication/
Ex-Merck & Co scientist accused of stealing trade secrets could face jailA former Merck & Co scientist could face up to 10 years in prison after he was accused Share XEx-Merck & Co scientist accused of stealing trade secrets could face jailhttps://pharmaphorum.com/news/merck-co-scientist-accused-of-stealing-trade-secrets-could-face-jail/
NICE recommends interim funding for GSK’s Zejula in ovarian cancerWomen with newly-diagnosed advanced ovarian cancer have a new treatment option in England after NICE recommend interim funding Share XNICE recommends interim funding for GSK’s Zejula in ovarian cancerhttps://pharmaphorum.com/news/nice-recommends-interim-funding-for-gsks-zejula-in-ovarian-cancer/
BI investigates cancer ‘dark antigens’ with UK’s EnaraBoehringer Ingelheim has signed a strategic collaboration with UK biotech Enara Bio, focused on finding ways to fight Share XBI investigates cancer ‘dark antigens’ with UK’s Enarahttps://pharmaphorum.com/news/boehringer-to-investigate-dark-antigens-with-uk-cancer-specialist-enara/
Pfizer deal paves way for approval of ImaginAb’s cancer imaging techImaginAb has signed a deal with Pfizer, which it hopes will help it to gather information necessary for Share XPfizer deal paves way for approval of ImaginAb’s cancer imaging techhttps://pharmaphorum.com/news/pfizer-deal-could-help-approval-of-imaginabs-cancer-imaging-tech/
Why cell therapy manufacture is a team sportLouis van de Wiel, Vice President, Site Head EU Manufacturing, Kite, a Gilead Company, reveals the complexity that Share XWhy cell therapy manufacture is a team sporthttps://pharmaphorum.com/market-access-2/why-cell-therapy-manufacture-is-a-team-sport/
BMS calls time on brain cancer trial as Opdivo misses second targetBristol Myers-Squibb has put out another downbeat “update” announcement about its immunotherapy Opdivo in an aggressive form of Share XBMS calls time on brain cancer trial as Opdivo misses second targethttps://pharmaphorum.com/news/bms-calls-time-on-brain-cancer-trial-as-opdivo-misses-second-target/
